High Growth Tech Stocks in the United States to Watch

In This Article:

Over the last 7 days, the United States market has dropped by 1.0%, but it has experienced a robust growth of 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain strong performance despite short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Sarepta Therapeutics

23.90%

42.65%

★★★★★★

Clene

78.50%

60.70%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Blueprint Medicines

25.47%

68.62%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Legend Biotech

Simply Wall St Growth Rating: ★★★★★☆

Overview: Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications globally, with a market cap of approximately $7.04 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $520.18 million. Its operations span the United States, China, and other international markets.

Legend Biotech's commitment to innovation is underscored by its recent establishment of a new R&D facility in Philadelphia, signaling an expansion in its capabilities to advance next-generation cell therapies. This move complements the company's robust investment in research, with R&D expenses constituting a significant portion of revenue, reflecting a strategic focus on sustaining its pipeline's growth and addressing complex medical needs. Despite reporting a net loss, Legend Biotech has shown remarkable revenue growth from $205.68 million to $440.72 million year-over-year, demonstrating potential in its operational scaling and market penetration. The approval and success of CARVYKTI® further illustrate Legend’s pivotal role in transforming treatment paradigms for multiple myeloma through advanced cell therapy technologies.

NasdaqGS:LEGN Revenue and Expenses Breakdown as at Nov 2024
NasdaqGS:LEGN Revenue and Expenses Breakdown as at Nov 2024

Corning

Simply Wall St Growth Rating: ★★★★☆☆